The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ivanets N.N.

Kafedra psikhiatrii i meditsinskoĭ psikhologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Kinkul'kina M.A.

Kafedra psikhiatrii i meditsinskoĭ psikhologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Avdeeva T.I.

Tikhonova Iu.G.

Kafedra psikhiatrii i narkologii GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova" Minzdrava RF;
Nauchno-obrazovatel'nyĭ klinicheskiĭ tsentr "Psikhicheskoe zdorov'e", Moskva

Lukyanova A.V.

Sechenov First Moscow State Medical University, Moscow

An increase in the efficacy of psychopharmacotherapy of late-onset depressions: combination and substitution of antidepressants

Authors:

Ivanets N.N., Kinkul'kina M.A., Avdeeva T.I., Tikhonova Iu.G., Lukyanova A.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(5): 43‑51

DOI: 10.17116/jnevro20161165143-51

Read: 17937 times

Download PDF (RU)
Contact the author
Table of contents

AN INCREASE IN THE EFFICACY OF PSYCHOPHARMACOTHERAPY OF LATE-ONSET DEPRESSIONS: COMBINATION AND SUBSTITUTION OF ANTIDEPRESSANTS
AN INCREASE IN THE EFFICACY OF PSYCHOPHARMACOTHERAPY OF LATE-ONSET DEPRESSIONS: COMBINATION AND SUBSTITUTION OF ANTIDEPRESSANTS

To cite this article:

Ivanets NN, Kinkul'kina MA, Avdeeva TI, Tikhonova IuG, Lukyanova AV. An increase in the efficacy of psychopharmacotherapy of late-onset depressions: combination and substitution of antidepressants. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(5):43‑51. (In Russ.)
https://doi.org/10.17116/jnevro20161165143-51

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
Posttraumatic stress diso­rder clinical guidelines and treatment standards: focus on the symptoms of the psychophysiological arousal. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):58-68
Pharmacogenomic and pharmacometabolomic biomarkers of the effi­cacy and safety of anti­depressants: focus on sele­ctive sero­tonin reuptake inhi­bitors. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):26-35
Mela­tonergic anti­depressant agomelatine: augmentation of anti­psychotic drugs in treatment of post-schizophrenic depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):5-12
Therapeutic targets of adolescent depression with atte­nuated symptoms of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):69-74
Open obse­rvational study with a retrospective analysis of the effi­cacy and tole­rability of aceclofenac in patients with acute non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):99-105
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
Sero­tonin syndrome: focus on opioid analgesics. Russian Journal of Pain. 2024;(3):98-106
Anti­depressants as addi­tional drugs for human brain gliomas. Burdenko's Journal of Neurosurgery. 2024;(6):97-102

Objective. To comprehensively analyze the possibilities of using the methods of correction of non-effective psychopharmacotherapy of late-onset depressions. Material and methods. Methods of potentiating, combination and substitution of non-effective psychopharmacotherapy of late-onset depressions were studied. Results and conclusion. Indications to the use and specific algorithms of substitution and addition of antidepressants in non-effective psychopharmacotherapy of late-onset depressions have been developed. These algorithms of combination therapy suggest the possibilities for choosing the individual combinations of antidepressants.

Keywords:

late age
psychopharmacotherapy
efficacy
antidepressants
resistance to psychopharmacotherapy
substitution of therapy
complex psychopharmacotherapy

Authors:

Ivanets N.N.

Kafedra psikhiatrii i meditsinskoĭ psikhologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Kinkul'kina M.A.

Kafedra psikhiatrii i meditsinskoĭ psikhologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Avdeeva T.I.

Tikhonova Iu.G.

Kafedra psikhiatrii i narkologii GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova" Minzdrava RF;
Nauchno-obrazovatel'nyĭ klinicheskiĭ tsentr "Psikhicheskoe zdorov'e", Moskva

Lukyanova A.V.

Sechenov First Moscow State Medical University, Moscow

List of references:

  1. Mosolov SN. Klinicheskoe primenenie sovremennyh antidepressantov. SPb.: MIA; 1995. (In Russ.).
  2. Dew MA, Whyte EM, Lenze EJ et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry. 2007;164:892-899.  doi: 10.1176/ajp.2007.164.6.892.
  3. Koncevoj VA, Rotshtejn VG, Safarova TP. i dr. Osobennosti ispol'zovanija antidepressantov v gerontopsihiatrii. Psihiatrija i psihofarmakoterapija. 2011;13:5:26-29. (In Russ.).
  4. Gareri P, Falconi U, De Fazio P, De Sarro G. Conventional and new antidepressant drugs in the elderly. Prog Neurobiol. 2000;61(4):353-396.  doi: 10.1016/s0301-0082(99)00050-7.
  5. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006;1:CD003491. doi: 10.1002/14651858.
  6. Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clin Ther. 2009;31(5):945-961.  doi: 10.1016/j.clinthera.2009.05.016.
  7. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16:558-567.  doi: 10.1097/01.jgp.0000308883.64832.ed.
  8. Nierenberg AA. Lessons from STEP-BD for the treatment of bipolar depression. Depress Anxiety. 2009;26(2):106-099.  doi: 10.1002/da.20547.
  9. Ivanec NN, Kinkul'kina MA, Avdeeva TI, Tihonova JuG, Luk'janova AV. Jeffektivnost' psihofarmakoterapii pozdnih depressij: optimizacija dlitel'nosti terapii. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2016;116:4. (In Russ.).
  10. Andrusenko MP. Vozrastnye aspekty terapii pozdnih depressij (kliniko-terapevticheskie zakonomernosti): Dis. ... d-ra med. nauk. M. 2004. Dostupno po: http://psychiatry.ru/cond/0/diss/2004/24. Ssylka aktivna na 30.08.15. (In Russ.).
  11. Semke VJa, Cygankov BD, Odarchenko SS. Osnovy pogranichnoj gerontopsihiatrii. M.: Medicina; 2006. (In Russ.).
  12. Smulevich AB. Depressii v obshhej medicine. M.: MIA; 2007. (In Russ.).
  13. Allard P, Gram L, Timdahl K et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry. 2004;19(12):1123-1130. doi: 10.1002/gps.1190.
  14. Arana GW, Rosenbaum JF. Handbook of Psychiatric Drug Therapy, 6th ed. LWW, Philadelphia; 2009.
  15. Blazer D. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci. 2003;58(3):249-265.  doi: 10.1093/gerona/58.3.m249.
  16. Copeland JR, Abou-Saleh M, Blazer D. Principles and Practice of Geriatric Psychiatry. 2nd ed. Chichester: John Wiley & Sons, Ltd; 2002.
  17. Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging. 2010;27(8):625-640.  doi: 10.2165/11537140-000000000-00000.
  18. Jacobson SA, Pies RW, Katz IR. Clinical Manual of Geriatric Psychopharmacology. Arlington: Am Psychiatr Publ; 2007.
  19. Kasper S, de Swart H, Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry. 2005;13(10):884-891.  doi: 10.1176/appi.ajgp.13.10.884.
  20. Kasper S, Hajak G, Wulff K et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle, depressive and anxiety symptoms in patients with major depressive disorder. A randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71:109-120.  doi: 10.4088/jcp.09m05347blu.
  21. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol. 2005;45:1106-1122. doi: 10.1177/0091270005280297.
  22. Mazeh D, Shahal B, Aviv A, Zemishlani H, Barak Y. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol. 2007;22(6):371-375.  doi: 10.1097/yic.0b013e32817396ae.
  23. Reynolds CF III, Dew MA, Pollock BG et al. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354:1130-1138. doi: 10.1056/nejmoa052619.
  24. Roose SP, Sackeim HA, Krishnan RR et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry. 2004;161:2050-2059. doi: 10.1176/appi.ajp.161.11.2050.
  25. Tedeschini E, Levkovitz Y, Iovieno N et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72(12):1660-1668. doi: 10.4088/jcp.10r06531.
  26. Thase ME, Entsuah R, Cantillon M, Kornstein SG. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt). 2005;14:609-616.  doi: 10.1089/jwh.2005.14.609.
  27. Barry LC, Abou JJ, Simen AA, Gill TM. Under-treatment of depression in older persons. J Affect Disord. 2012;136(3):789-796.  doi: 10.1016/j.jad.2011.09.038.
  28. Burns A, Lawlor B, Craig S. Rating scales in old age psychiatry. Br J Psychiatry. 2002;180:161-167.  doi: 10.1192/bjp.180.2.161.
  29. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.  doi: 10.1192/bjp.134.4.382.
  30. Avruckij GJa, Neduva AA. Lechenie psihicheski bol'nyh. M.: Medicina; 1988. (In Russ.).
  31. Krasnov VH. Rasstrojstva affektivnogo spektra. M.: Prakticheskaja medicina; 2011. (In Russ.).
  32. Medvedev VJe. Primenenie val'doksana (agomelatina) v kombinirovannoj terapii umerenno vyrazhennyh i tjazhelyh depressij nepsihoticheskogo urovnja. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;112:5:37-40. (In Russ.).
  33. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43-64.  doi: 10.2165/11587620-000000000-00000.
  34. Martín-López LM, Rojo JE, Gibert K et al. The strategy of combining antidepressants in the treatment of major depression: clinical experience in spanish outpatients. Depress Res Treat. 2011;140194. doi: 10.1155/2011/140194.
  35. Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24(2):131-161.  doi: 10.2165/11530280-000000000-00000.
  36. Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252. doi: 10.1056/nejmoa052964.
  37. Rebrova OJu. Statisticheskij analiz medicinskih dannyh. Primenenie paketa prikladnyh programm STATISTICA. M.: Mediasfera; 2002. (In Russ.).
  38. Meyers BS, Flint AJ, Rothschild AJ et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression. Arch Gen Psychiatry. 2009;66:838-847.  doi: 10.1001/archgenpsychiatry.2009.79.
  39. Petrovic M, De Paepe P, Van Bortel L. Pharmacotherapy of depression in old age. Acta Clin Belg. 2005;60(3):150-156.  doi: 10.1179/acb.2005.028.
  40. Mazo GJe, Shmaneva TM, Krizhanovskij AS. Primenenie kombinirovannoj terapii antidepressantami dlja lechenija depressii: vzgljad na problemu. Obozrenie psihiatrii i med psihologii im. V.M. Behtereva. 2010;4:15-19. (In Russ.).
  41. Alexopoulos GS. Pharmacotherapy for late-life depression. J Clin Psychiatry. 2011;72(1):04.  doi: 10.4088/jcp.7085tx2cj.
  42. Aziz R, Lorberg B, Tampi RR. Treatments for late-life bipolar disorder. Am J Geriatr Pharmacother. 2006;4(4):347-364.  doi: 10.1016/j.amjopharm.2006.12.007.
  43. Berman RM, Fava M, Thase ME et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
  44. Cooper C, Katona C, Lyketsos K et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011;168(7):681-688.  doi: 10.1176/appi.ajp.2011.10081165.
  45. Dunner D, Amsterdam JD, Shelton RC et al. Adjunctive ziprasidone for resistant depression: 8-week pilot study. Eur Neuropsychopharmacol. 2005;15(3):444.  doi: 10.1016/s0924-977x(05)80910-1.
  46. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649-659.  doi: 10.1016/s0006-3223(03)00231-2.
  47. Lenze EJ, Sheffrin M, Driscoll HC et al. Incomplete response in late-life depression: getting to remission. Dialogues Clin Neurosci. 2008;10(4):419-430.
  48. Nelson JC, Papakostas G. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166:980-991.  doi: 10.1176/appi.ajp.2009.09030312.
  49. Rapaport MH, Gharabawi GM, Canuso CM et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31(11):2505-2513. doi: 10.1038/sj.npp.1301113.
  50. Rothschild AJ, Williamson DJ, Tohen MF et al. A double blind, randomized study of olanzapine and olanzapine fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004;24(4):365-73.  doi: 10.1097/01.jcp.0000130557.08996.7a.
  51. Rutherford B, Sneed J, Miyazaki M et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int J Geriatr Psychiatry. 2007;22(10):986-991.  doi: 10.1002/gps.1775.
  52. Steffens D, McQuoid D, Krishnan K. The Duke somatic treatment algorithm for geriatric depression [STAGED] approach. Psychopharmacol Bull. 2002;36:58-68.
  53. Mulsant BH, Sweet RA, Rosen J et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry. 2001;62(8):597-604.  doi: 10.4088/jcp.v62n0804.
  54. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81-109.  doi: 10.3109/15622970903555881.
  55. Ivanec NN, Kinkul'kina MA, Avdeeva TI. Klasternyj analiz simptomov depressii u bol'nyh pozhilogo vozrasta. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2012;112:7:10-19. (In Russ.).
  56. Andreescu C, Mulsant BH, Houck PR et al. Empirically derived decision trees for the treatment of late-life depression. Am J Psychiatry. 2008;165:855-862.  doi: 10.1176/appi.ajp.2008.07081340.
  57. Rossini D, Serretti A, Franchini L et al. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol. 2005;25:471-475.  doi: 10.1097/01.jcp.0000177548.28961.e7.
  58. Jefferson J. Strategies for switching antidepressants to achieve maximum efficacy. J Clin Psychiatry. 2008;69(suppl.E1):14-18.
  59. Rush AJ, Trivedi MH, Wisniewski SR et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242. doi: 10.1056/nejmoa052963.
  60. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging. 2001;18(5):355-368.  doi: 10.2165/00002512-200118050-00006.
  61. Malhi GS, Parker GB, Crawford J et al. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand. 2005;112:302-309.  doi: 10.1111/j.1600-0447.2005.00602.x.
  62. Mancini C, Van Ameringen M, Farvolden P. Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder? J Affect Disord. 2002;68(1):59-65.  doi: 10.1016/s0165-0327(00)00326-8.
  63. Rojo JE, Ros S, Agüera L, De La Gándara J, De Pedro JM. Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl. 2005;112(428):25-31.  doi: 10.1111/j.1600-0447.2005.00677.x.
  64. Szegedi A, Wetzel H, Leal M et al. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry. 1996;57:257-264.
  65. Blier P, Gobbi G, Turcotte JE et al. Mirtazapine and paroxetine in major depression. A comparison of monotherapy versus their combination from treatment initiation. J Eur Neuropharm. 2009;19:457-465.  doi: 10.1016/j.euroneuro.2009.01.015.
  66. Debonnel G, Gobbi G, Turcotte J et al. Effects of mirtazapine, paroxetine and their combination: a double-blind study in major depression. Eur Neuropsychopharmacol. 2000;10(3):252.  doi: 10.1016/s0924-977x(00)80213-8.
  67. Mulder RT, Watkins WG, Joyce PR, Luty SE. Age may affect response to antidepressants with serotonergic and noradrenergic actions. J Affect Disord. 2003;76(1-3):143-149.  doi: 10.1016/s0165-0327(02)00083-6.
  68. McGrath PJ, Stewart JW, Fava M et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STAR*D Report. Am J Psychiatry. 2006;163(9):1531-1541. doi: 10.1176/appi.ajp.163.9.1531.
  69. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl.). 2002;161:143-151.  doi: 10.1007/s00213-002-0999-0.
  70. Maes M, Libbrecht I, Van Hunsel F et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol. 1999;19:177-182.  doi: 10.1097/00004714-199904000-00014.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.